NasdaqCM - Nasdaq Real Time Price ? USD Cingulate Inc. (CING) Follow Compare 4.9200 +0.3300 (+7.19%) At close: October 21 at 4:00 PM EDT 5.0000 +0.08 (+1.63%) After hours: October 21 at 7:27 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Cingulate’s Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show KANSAS CITY, Kan., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Shane J. Schaffer, Chairman and CEO of Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release? (PTR?) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, recently joined the cast of the Big Biz Show, a business and finance broadcast, to discuss Cingulate’s lead Phase 3 asset CTx-1301 for the treatment of ADHD, its plans for commercia GlobeNewswire ? 13 days ago CING +7.19% CINGW Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301 $10 Million of additional Capital Recently Raised Strengthening Balance SheetKANSAS CITY, Kan., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release? (PTR?) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it has commenced its final FDA-required study, which is a food effect study, for CTx-1301 (dexmethylphenidate) for the tr GlobeNewswire ? last month CING +7.19% CINGW Cingulate to Participate in Benzinga All Live Access Event KANSAS CITY, Kan., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release? (PTR?) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer, PharmD, will participate in a live Benzinga All Access event on August 28, 2024, at 10:30 a.m. CST. Along with a company overview, Dr. Schaffer will discuss Cingul GlobeNewswire ? last month CING +7.19% CINGW CING: Initiating Coverage – Precision Timed Release Delivers Active-Day Coverage By John Vandermosten, CFA NYSE:CING READ THE FULL CING RESEARCH REPORT We are initiating coverage of Cingulate, Inc. (NYSE:CING) with a target price of $70.00 per share. This value is based on our forecasts for the successful development and commercialization of CTx-1301 for Attention Deficit/ Hyperactivity Disorder (ADHD). Cingulate’s candidate uses its licensed precision timed release (PTR) Zacks Small Cap Research ? last month CINGW Cingulate Announces Adjournment of Special Meeting KANSAS CITY, Kan., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), (“Cingulate” or the “Company”), a biopharmaceutical company utilizing its proprietary Precision Timed Release? (PTR?) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that it has adjourned its Special Meeting of Stockholders (the “Special Meeting”) in order to provide stockholders additional time within which to vote on all proposals. At GlobeNewswire ? last month CING +7.19% CINGW Top Midday Decliners Top Midday Decliners PREMIUM MT Newswires ? 2 months ago CINGW LQDA Top Midday Gainers Top Midday Gainers PREMIUM MT Newswires ? 2 months ago CINGW Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD KANSAS CITY, Kan., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release? (PTR?) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it was issued a European patent for its lead asset CTx-1301 (dexmethylphenidate) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The patent application was granted on August 14, GlobeNewswire ? 2 months ago CING +7.19% CINGW Cingulate Reports Second Quarter 2024 Financial Results?and Provides Development Update on Major Milestones Achieved FDA Clears Cingulate to File for Marketing Approval of CTx-1301 targeted in 1H 2025Licensing Activity Continues KANSAS CITY, Kan., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release? (PTR?) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the three months ended June 30, 2024, and provided a clinical and GlobeNewswire ? 2 months ago CING +7.19% CINGW Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds KANSAS CITY, Kan., June 28, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (the “Company”) (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release? (PTR?) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the entry into definitive agreements for the immediate exercise of certain outstanding Series A warrants to purchase up to an aggregate of 2,125,000 shares of common stock of the Company a GlobeNewswire ? 3 months ago CING +7.19% CINGW Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event KANSAS CITY, Kan., June 25, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release? (PTR?) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer, PharmD, and preeminent board-certified psychiatrist and Cingulate scientific advisor Dr. Ann Childress, MD, will participate in a live Benzinga All Access event on GlobeNewswire ? 3 months ago CING +7.19% CINGW Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance Twelve Required Registration Batches CompletedNew Drug Application Being Prepped for Submission KANSAS CITY, Kan., June 25, 2024 (GLOBE NEWSWIRE) -- In alignment with U.S. Food and Drug Administration (FDA) requirements, Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release? (PTR?) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it has completed the manufactur GlobeNewswire ? 3 months ago CING +7.19% CINGW FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD Cingulate's Precision Timed Release Technology? (PTR?) Platform Technology Cingulate? is developing ADHD product candidates capable of achieving true once-daily dosing using the Company’s innovative Precision Timed Release? (PTR?) drug delivery platform technology incorporating a proprietary Erosion Barrier Layer (EBL) that provides control of drug release at precise, pre-defined times with no release of drug prior to the intended release.The technology is an erodible barrier layer that is wrapp GlobeNewswire ? 4 months ago CING +7.19% CINGW Cingulate Reports First Quarter 2024 Financial Results?and Provides Clinical and Business Update CTx-1301 on track to file for Marketing Approval with FDA in 1H 2025 Increase of $10 Million in Stockholders’ Equity KANSAS CITY, Kan., May 08, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release? (PTR?) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the three months ended March 31, 2024, and provided a clinical GlobeNewswire ? 5 months ago CING +7.19% CINGW Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access KANSAS CITY, Kan., April 30, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release? (PTR?) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that longstanding Cingulate investor and board member Peter J. Werth will join Cingulate Chairman and CEO Shane J. Schaffer in a live Benzinga All Access event on Friday May 3, 2024, at 12:10 p.m. EST. M GlobeNewswire ? 5 months ago CING +7.19% CINGW Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV LAS VEGAS, NV / ACCESSWIRE / April 29, 2024 / Planet MicroCap presents the Planet MicroCap Showcase: VEGAS taking place on April 30 - May 2, 2024, where 96 MicroCap public and private companies will be presenting at the Paris Hotel & Casino in Las ... ACCESSWIRE ? 5 months ago DCMDF DDC CKT.L Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024 KANSAS CITY, Kan., April 16, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release? (PTR?) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that it will present at the Planet MicroCap Showcase: VEGAS 2024 conference on Wednesday, May 1, 2024, at 2:30 PM PST. Management will also host individual investor meetings on Thursday, May 2. Meetings GlobeNewswire ? 6 months ago CING +7.19% CINGW Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results?and Provides Clinical and Business Update $17.8 Million Raised Since Beginning of 2023$9.1 Million of Debt Converted to Equity at a PremiumPhase 3 ADHD Data Continues to Impress KANSAS CITY, Kan., April 01, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release? (PTR?) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the twelve months ended December 31, 2023 GlobeNewswire ? 6 months ago CING +7.19% CINGW Cingulate to Attend DCAT Week 2024 in New York City Will Host Licensing Meetings with Multiple Parties to Discuss Assets, Pipeline and TechnologyKANSAS CITY, Kan., March 06, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release? (PTR?) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it will be attending DCAT Week (Drug, Chemical & Associated Technologies Association) March 18-21, 2024, GlobeNewswire ? 7 months ago CING +7.19% CINGW Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors Announcement Follows Recent Public Offering and Successful Capital Raising ActivityKANSAS CITY, Kan., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release? (PTR?) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it has appointed three new directors to its board: Jay Roberts, Bryan Lawrence, and Jeff Ervin. The appointment of t GlobeNewswire ? 8 months ago BACK CING +7.19% CINGW Performance Overview Trailing total returns as of 10/21/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return CING S&P 500 YTD -94.64% +22.73% 1-Year -95.64% +38.58% 3-Year -99.59% +24.52%
